Decay-accelerating factor (DAF; CD55)
Choi-Miura, N.H.
Nihon Rinsho. Japanese Journal of Clinical Medicine 57 Suppl: 79-81
1999
ISSN/ISBN: 0047-1852 PMID: 10635780 Document Number: 500849
Document emailed within 1 workday
Related Documents
Iwata, K.; Seya, T.; Ariga, H.; Nagasawa, S. 1994: Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein Journal of Immunology 152(7): 3436-3444Post, T.W.; Arce, M.A.; Liszewski, M.K.; Thompson, E.S.; Atkinson, J.P.; Lublin, D.M. 1990: Structure of the gene for human complement protein decay accelerating factor Journal of Immunology 144(2): 740-744
Shibuya, K.; Abe, T.; Fujita, T. 1992: Decay-accelerating factor functions as a signal transducing molecule for human monocytes Journal of Immunology 149(5): 1758-1762
Kammer, G.M.; Walter, E.I.; Medof, M.E. 1988: Association of cytoskeletal re-organization with capping of the complement decay-accelerating factor on T lymphocytes Journal of Immunology 141(9): 2924-2928
Quigg, R.J.; Nicholson-Weller, A.; Cybulsky, A.V.; Badalamenti, J.; Salant, D.J. 1989: Decay accelerating factor regulates complement activation on glomerular epithelial cells Journal of Immunology 142(3): 877-882
Brodbeck, W.G.; Liu, D.; Sperry, J.; Mold, C.; Medof, M.E. 1996: Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor Journal of Immunology 156(7): 2528-2533
Shibata, T.; Cosio, F.G.; Birmingham, D.J. 1991: Complement activation induces the expression of decay-accelerating factor on human mesangial cells Journal of Immunology 147(11): 3901-3908
Higgins, P.J.; Ko, J.L.; Lobell, R.; Sardonini, C.; Alessi, M.K.; Yeh, C.G. 1997: A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities Journal of Immunology 158(6): 2872-2881
Coyne, K.E.; Hall, S.E.; Thompson, S.; Arce, M.A.; Kinoshita, T.; Fujita, T.; Anstee, D.J.; Rosse, W.; Lublin, D.M. 1992: Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor Journal of Immunology 149(9): 2906-2913
Ward, T.; Pipkin, P.A.; Clarkson, N.A.; Stone, D.M.; Minor, P.D.; Almond, J.W. 1994: Decay-accelerating factor CD55 is identified as the receptor for echovirus 7 using CELICS, a rapid immuno-focal cloning method EMBO Journal 13(21): 5070-5074
Richards, A.C.; Tucker, A.W.; Carrington, C.A.; White, D.J. 1996: Reduced human neutrophil adhesion to porcine endothelia expressing human decay accelerating factor Transplantation Proceedings 28(2): 636
Cary, N.; Moody, J.; Yannoutsos, N.; Wallwork, J.; White, D. 1993: Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection Transplantation Proceedings 25(1 Pt 1): 400-401
Pearce, E.J.; Hall, B.F.; Sher, A. 1990: Host-specific evasion of the alternative complement pathway by schistosomes correlates with the presence of a phospholipase C-sensitive surface molecule resembling human decay accelerating factor Journal of Immunology 144(7): 2751-2756
Ramirez, P.; Chavez, R.; Majado, M.; Munitiz, V.; Muñoz, A.; Hernandez, Q.; Palenciano, C.G.; Pino-Chavez, G.; Loba, M.; Minguela, A.; Yelamos, J.; Gago, M.R.; Vizcaino, A.S.; Asensi, H.; Cayuela, M.G.; Segura, B.; Marin, F.; Rubio, A.; Fuente, T.; Robles, R.; Bueno, F.S.; Sansano, T.; Acosta, F.; Rodriguez, J.M.; Navarro, F.; Cabezuelo, J.; Cozzi, E.; White, D.J.; Calne, R.Y.; Parrilla, P. 2000: Life-supporting human complement regulator decay accelerating factor transgenic pig liver xenograft maintains the metabolic function and coagulation in the nonhuman primate for up to 8 days Transplantation 70(7): 989-998
Rosengard, A.M.; Cary, N.; Horsley, J.; Belcher, C.; Langford, G.; Cozzi, E.; Wallwork, J.; White, D.J. 1995: Endothelial expression of human decay accelerating factor in transgenic pig tissue: a potential approach for human complement inactivation in discordant xenografts Transplantation Proceedings 27(1): 326-327
Nicholson-Weller, A.; Burge, J.; Fearon, D.T.; Weller, P.F.; Austen, K.F. 1982: Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system Journal of Immunology 129(1): 184-189
Sima, A.; Hobai, I.; Stancu, C.; Cinteză, M.; Gherasim, L. 1996: Correlated biochemical modifications of plasma lipoproteins in coronary heart disease: an accelerating pathologic factor Romanian Journal of Internal Medicine 34(1-2): 55-64
Fearon, D.T.; Austen, K.F.; Ruddy, S. 1973: Serum proteins involved in decay and regeneration of cobra venom factor-dependent complement activation Journal of Immunology 111(6): 1730-1736
Korolev, V.G.; Ivanov, E.L. 1979: Genetic effects of sulfur-35 decay in Saccharomyces cerevisiae cells. V. Comparative study of the lethal and mutagenic effectiveness of the decay of 35S and 32P incorporated into cells of the radiosensitive mutant xrs2 Genetika 15(6): 1024-1032
Reed, G.L.; Matsueda, G.R.; Haber, E.; Haber, E. 1992: Platelet factor XIIi increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin Thrombosis and Haemostasis 68(3): 315-320